Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
Pubmed

Identification of Glis1, a novel Gli-related, Kruppel-like zinc finger protein containing transactivation and repressor functions.

GLIS3 GLIS1

6.25e-07228212042312
Pubmed

GLIS3, a novel member of the GLIS subfamily of Krüppel-like zinc finger proteins with repressor and activation functions.

GLIS3 GLIS1

1.87e-06328214500813
Pubmed

Gene of the month: GLIS1-3.

GLIS3 GLIS1

1.87e-06328232699115
Pubmed

Functional analysis of the zinc finger and activation domains of Glis3 and mutant Glis3(NDH1).

GLIS3 GLIS1

1.87e-06328218263616
Pubmed

(-)-Epigallocatechin-3-gallate alleviates spatial memory impairment in APP/PS1 mice by restoring IRS-1 signaling defects in the hippocampus.

IRS1 APP

1.87e-06328223660953
Pubmed

Knock-in of diphteria toxin A chain gene at Ins2 locus: effects on islet development and localization of Ins2 expression in the brain.

IRS1 PPY

4.10e-051228215587270
Pubmed

The Spatiotemporal Pattern of Glis3 Expression Indicates a Regulatory Function in Bipotent and Endocrine Progenitors during Early Pancreatic Development and in Beta, PP and Ductal Cells.

GLIS3 PPY

5.65e-051428227270601
Pubmed

Extensive proteomic screening identifies the obesity-related NYGGF4 protein as a novel LRP1-interactor, showing reduced expression in early Alzheimer's disease.

APP SNRNP70

6.52e-051528220205790
Pubmed

The negative regulator of Gli, Suppressor of fused (Sufu), interacts with SAP18, Galectin3 and other nuclear proteins.

SETDB1 MACROH2A1

1.18e-042028214611647
Pubmed

Transcription factor Glis3, a novel critical player in the regulation of pancreatic beta-cell development and insulin gene expression.

GLIS3 PPY

1.56e-042328219805515
Pubmed

The Krüppel-like zinc finger protein GLIS3 transactivates neurogenin 3 for proper fetal pancreatic islet differentiation in mice.

GLIS3 PPY

1.85e-042528221786021
Pubmed

BCAR1 promotes proliferation and cell growth in lung adenocarcinoma via upregulation of POLR2A.

DOCK2 ESRP2 APP YIPF6

3.38e-0441928433001583
Pubmed

RioK1, a new interactor of protein arginine methyltransferase 5 (PRMT5), competes with pICln for binding and modulates PRMT5 complex composition and substrate specificity.

RPL21 ESRP2 MACROH2A1 SNRNP70

3.57e-0442528421081503
Pubmed

Comparative Interactomes of VRK1 and VRK3 with Their Distinct Roles in the Cell Cycle of Liver Cancer.

RPL21 MACROH2A1 SDR42E2

5.93e-0420528328927264
Pubmed

USP48 Is Upregulated by Mettl14 to Attenuate Hepatocellular Carcinoma via Regulating SIRT6 Stabilization.

MACROH2A1 APP

6.61e-044728233903120
CoexpressionGSE37319_WT_VS_RC3H1_KO_CD44LOW_CD8_TCELL_DN

GLIS3 NDST3 LPCAT3 GPR173

1.21e-05139274M8919
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

SETDB1 IRS1 USP46 ALG12 PLXNB1

2.28e-061772853177_DN
DrugIle-Asn

APP PPY

1.46e-055282CID004414300
DrugParthenolide [20554-84-1]; Down 200; 16.2uM; MCF7; HT_HG-U133A

SETDB1 IRS1 USP46 PLXNB1

4.53e-051632842885_DN
DrugAd19

AOC1 APP

5.22e-059282CID000126394
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

ESRP2 SETDB1 IRS1 APP

6.11e-051762842639_DN
DrugAC1L5KHX

IRS1 APP

6.52e-0510282CID000276752
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

ESRP2 SETDB1 IRS1 CDK10

6.67e-051802846454_DN
Drugtrichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A

SETDB1 IRS1 USP46 APP

6.67e-051802846886_DN
Druggeldanamycin; Down 200; 1uM; MCF7; HT_HG-U133A

ESRP2 SETDB1 MACROH2A1 APP

7.42e-051852845225_DN
Drug2-propylpentanoic acid; Down 200; 10000uM; MCF7; HG-U133A

ESRP2 SETDB1 IRS1 CDK10

7.89e-05188284345_DN
DrugNilutamide [63612-50-0]; Down 200; 12.6uM; PC3; HT_HG-U133A

SETDB1 APP PLXNB1 CNTNAP2

8.91e-051942846763_DN
DrugEstradiol-17 beta [50-28-2]; Down 200; 14.6uM; MCF7; HT_HG-U133A

ESRP2 USP46 RNASEL YIPF6

9.09e-051952845318_DN
DrugLiothyronine [6893-02-3]; Down 200; 6.2uM; MCF7; HT_HG-U133A

SETDB1 APP ALG12 CDK10

9.09e-051952844947_DN
DrugCiprofloxacin hydrochloride [93107-08-5]; Down 200; 10.8uM; MCF7; HT_HG-U133A

MACROH2A1 APP LPCAT3 PLXNB1

9.09e-051952841522_DN
DrugNiridazole [61-57-4]; Up 200; 18.6uM; HL60; HT_HG-U133A

RNASEL SNRNP70 ALG12 CNTNAP2

9.28e-051962842440_UP
DrugMoroxidine hydrochloride [3160-91-6]; Down 200; 19.2uM; MCF7; HT_HG-U133A

SETDB1 RNASEL APP CDK10

9.46e-051972845304_DN
DrugIdazoxan hydrochloride [79944-56-2]; Down 200; 16.6uM; PC3; HT_HG-U133A

SETDB1 APP PLXNB1 CNTNAP2

9.46e-051972846747_DN
DrugTocopherol (R,S) [10191-41-0]; Down 200; 9.2uM; HL60; HT_HG-U133A

SETDB1 EXT2 USP46 CDK10

9.65e-051982841320_DN
DrugButylparaben [94-26-8]; Down 200; 20.6uM; MCF7; HT_HG-U133A

MACROH2A1 APP CDK10 PLXNB1

9.65e-051982846446_DN
DrugGabapentin [60142-96-3]; Down 200; 23.4uM; PC3; HT_HG-U133A

MACROH2A1 APP ALG12 CNTNAP2

9.84e-051992845875_DN
DrugLY-171,883; Up 200; 1uM; MCF7; HG-U133A

APP CDK10 PLXNB1 GPR173

9.84e-05199284222_UP
DrugNaftopidil dihydrochloride [57149-08-3]; Down 200; 8.6uM; MCF7; HT_HG-U133A

ESRP2 RNASEL ALG12 LPCAT3

9.84e-051992847331_DN
Drugestradiol, USP; Down 200; 0.01uM; PC3; HT_HG-U133A

SETDB1 ALG12 YIPF6 CNTNAP2

9.84e-051992841241_DN
DrugTriflupromazine hydrochloride [1098-60-8]; Down 200; 10.2uM; PC3; HT_HG-U133A

SETDB1 APP ALG12 CDK10

9.84e-051992841813_DN
Diseasevisual epilepsy (is_implicated_in)

APP CNTNAP2

4.09e-0511262DOID:11832 (is_implicated_in)
Diseasetype 2 diabetes mellitus (implicated_via_orthology)

GLIS3 IRS1 GLIS1

1.07e-04105263DOID:9352 (implicated_via_orthology)
Diseaseinterleukin 5 measurement

SETDB1 CNTNAP2

2.78e-0428262EFO_0008185
Diseaseautistic disorder (is_implicated_in)

SETDB1 CNTNAP2

6.29e-0442262DOID:12849 (is_implicated_in)
DiseaseBipolar Disorder

NDST3 USP46 APP CNTNAP2

7.60e-04477264C0005586
DiseaseAlzheimer's disease (biomarker_via_orthology)

IRS1 APP

1.20e-0358262DOID:10652 (biomarker_via_orthology)
DiseasePROSTATE CANCER, HEREDITARY, 1

DOCK2 RNASEL

1.28e-0360262C4722327
DiseaseAlzheimer's disease (is_marker_for)

IRS1 APP SNRNP70

1.46e-03257263DOID:10652 (is_marker_for)
DiseaseProstate cancer, familial

DOCK2 RNASEL

1.69e-0369262C2931456
Diseasep-tau measurement

GLIS3 IRS1

1.84e-0372262EFO_0004763
Diseasenucleotide measurement

DOCK2 AOC1

1.89e-0373262EFO_0010513
Diseaseintellectual disability (implicated_via_orthology)

NDST3 IRS1

1.99e-0375262DOID:1059 (implicated_via_orthology)
Diseaseresponse to angiotensin-converting enzyme inhibitor

PPY CNTNAP2

2.15e-0378262EFO_0005325
Diseasemitochondrial DNA measurement

PPY CDK10 CNTNAP2

2.93e-03328263EFO_0006312

Protein segments in the cluster

PeptideGeneStartEntry
RPRHVFNMLKKYVRA

APP

486

P05067
FHLGIRKIMRTLYKK

GJA10

231

Q969M2
GRMLRYIKKGHPKYR

MACROH2A1

26

O75367
LIEMLLPKKYHVLRF

AOC1

71

P19801
PHKELRFIIYAFPML

ALG12

306

Q9BV10
KPARYRRGFIHKNIM

NDST3

456

O95803
MRYGFVRKKHRGLFL

PAPPA-AS1

1

Q5QFB9
PLYMLFRGIKHQVDK

PLXNB1

1706

O43157
IITKRRLHKPMYYFL

OR51T1

51

Q8NGJ9
LFILPYIHKAMVPRK

LPCAT3

466

Q6P1A2
VGYLRKPKSMHKRFF

IRS1

16

P35568
YINMLTRPRYGKRHK

PPY

56

P01298
RGYLIKHKMLQGIFP

DOCK2

46

Q92608
GLRLLHFLFMYDPKK

CDK10

296

Q15131
KPFNARYKLLIHMRV

GLIS3

391

Q8NEA6
KLLLFEYRHRKMKPV

GPR173

206

Q9NS66
DGHVVLPYRFRNKKM

CNTNAP2

191

Q9UHC6
PRVAGHIKKRLFMFR

SDR42E2

221

A6NKP2
KPFNARYKLLIHMRV

GLIS1

241

Q8NBF1
YGPIKRIHMVYSKRS

SNRNP70

126

P08621
HRIYRPMIGKLKFFI

RNASEL

351

Q05823
RHKGMLGKRYIELFR

ESRP2

421

Q9H6T0
RVNRKMGFHVIYKTP

SETDB1

616

Q15047
MLPLKVKGRRFYFLL

TMEM223

166

A0PJW6
LKAVGKKFMHVLYPR

YIPF6

66

Q96EC8
PRMKTKHRIYYITLF

EXT2

16

Q93063
KHGVVPLATYMRIYK

RPL21

21

P46778
KLPMILALHLKRFKY

USP46

246

P62068